NEW YORK - Ovid Therapeutics Inc . (NASDAQ: NASDAQ:OVID), a biopharmaceutical company, has released findings from preclinical studies indicating that its developmental drug OV329 may offer a new approach for treating drug-resistant seizures. The studies, published in the journal eNeuro, suggest that OV329, a GABA-aminotransferase (GABA-AT) inhibitor, could be more potent and safer than existing treatments.
The preclinical experiments, conducted in collaboration with the Department of Neuroscience at Tufts University School of Medicine and the Department of Neuroscience, Physiology and Pharmacology at University College London, demonstrated that OV329 reduced GABA-AT activity and increased GABA levels in the brain. This led to a decrease in the severity of status epilepticus, a potentially life-threatening state of continuous seizure activity, and prevented the onset of benzodiazepine-resistant seizures in mice.
In comparison to vigabatrin, a currently approved GABA-AT inhibitor, OV329 displayed superior potency, with an IC50 value significantly lower than that of vigabatrin. This could imply a lower required dosage and potentially fewer side effects in human patients.
Zhong Zhong, Ph.D., Chief Scientific Officer of Ovid Therapeutics, expressed confidence in the drug's differentiated profile and its potential to provide sustained seizure control. While OV329 has shown encouraging results in animal models, it is important to note that these findings are preliminary and further research is needed to confirm its efficacy and safety in humans.
The company is developing OV329 for rare and treatment-resistant forms of epilepsy, including conditions like status epilepticus, tuberous sclerosis complex, and infantile spasms. Ovid Therapeutics is also working on other novel treatments for epilepsies and related brain conditions.
In other recent news, Ovid Therapeutics has been the focus of several analyst reviews following the release of mixed clinical trial results. The company's Phase 1 study of its ROCK2 inhibitor, OV888, yielded promising results with no serious adverse events reported, leading TD (TSX:TD) Cowen to maintain its Buy rating on Ovid's shares. The drug is being developed to treat cerebral cavernous malformations, a condition characterized by abnormal blood vessels in the brain and spinal cord.
Conversely, the company experienced setbacks in its Phase 3 trials for soticlestat, a treatment for epilepsy syndromes. Despite not meeting primary goals in trials for Dravet and Lennox-Gastaut syndromes, the drug showed promising results in several secondary endpoints.
In response to these outcomes, analyst firms such as H.C. Wainwright, BTIG, and B.Riley maintained their Buy ratings but reduced their share target prices. However, Oppenheimer downgraded the stock from Outperform to Perform.
Despite the mixed results, Ovid Therapeutics remains committed to advancing its drug development pipeline and optimizing resource allocation. The company, in collaboration with its partners, continues to assess the next steps for the development of its various drugs. These recent developments underscore the company's ongoing efforts to strategically prioritize its programs and extend its cash runway into the first half of 2026.
InvestingPro Insights
Ovid Therapeutics Inc. (NASDAQ: OVID) has been making strides with its developmental drug OV329, aimed at treating drug-resistant seizures. As the company progresses with its preclinical studies, potential investors and stakeholders are keeping a close eye on its financial health and stock performance. Here are some key insights based on real-time data and InvestingPro Tips:
The company's market capitalization stands at a modest 58.88 million USD, reflecting its status as a smaller player in the biopharmaceutical industry. Despite the challenges faced by many companies in this sector, Ovid Therapeutics holds more cash than debt on its balance sheet, which could provide a cushion as it continues to fund its research and development efforts. This is a critical factor for investors considering the long-term viability of the company.
From a stock performance perspective, Ovid's stock has experienced significant return over the last week, with a 10.4% price total return. This could be indicative of positive investor sentiment following the recent preclinical study announcements. However, it's important to note that the stock has fared poorly over the last month, with a price total return of -73.23%. Analysts anticipate a sales decline in the current year, which may be a concern for those looking at the company's revenue-generating potential in the short term.
For investors seeking more in-depth analysis, there are additional InvestingPro Tips available that could provide further insights into Ovid Therapeutics' financial health and stock performance. For instance, the Relative Strength Index (RSI) suggests the stock is in oversold territory, which could imply a potential rebound or at least a stabilization of the stock price. Moreover, two analysts have revised their earnings upwards for the upcoming period, hinting at a more optimistic outlook for the company's financial future.
To explore these and other expert insights, visit InvestingPro at: https://www.investing.com/pro/OVID. Don't forget to use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, unlocking access to a total of 16 additional InvestingPro Tips that could help you make more informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.